Full Text
Cost-Effectiveness Analysis of Palivizumab as a Prophylaxis for Respiratory Syncytial Virus (RSV) Infection in High-Risk Late Preterm Infants in the Netherlands

Abstract

Authors

M.K. Langenfeld S. Visser

Back to Volume 16, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×